These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 7700741

  • 1. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Hemming VG.
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC.
    N Engl J Med; 1993 Nov 18; 329(21):1524-30. PubMed ID: 8413475
    [Abstract] [Full Text] [Related]

  • 3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 18; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 4. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B, Müller W.
    Klin Padiatr; 1999 Sep 18; 211(6):450-5. PubMed ID: 10592925
    [Abstract] [Full Text] [Related]

  • 5. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 18; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 6. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.
    Pediatrics; 1997 Mar 18; 99(3):454-61. PubMed ID: 9041304
    [Abstract] [Full Text] [Related]

  • 7. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children.
    Groothuis JR.
    J Pediatr; 1994 May 18; 124(5 Pt 2):S28-32. PubMed ID: 8169755
    [Abstract] [Full Text] [Related]

  • 8. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan 18; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G, Logvinoff MM, Zegarra N, Allen L, Jesurun A, Levin G, Thida A.
    Tex Med; 2000 May 18; 96(5):58-61. PubMed ID: 10843015
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
    Pediatrics; 1997 Apr 18; 99(4):645-50. PubMed ID: 9093323
    [Abstract] [Full Text] [Related]

  • 14. Role of antibody and the use of respiratory syncytial virus immunoglobulin in the prevention of respiratory syncytial virus disease in preterm infants with and without bronchopulmonary dysplasia.
    Groothuis JR.
    Pediatr Infect Dis J; 1994 May 18; 13(5):454-7; discussion 457-8. PubMed ID: 8072836
    [Abstract] [Full Text] [Related]

  • 15. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation.
    Cortez K, Murphy BR, Almeida KN, Beeler J, Levandowski RA, Gill VJ, Childs RW, Barrett AJ, Smolskis M, Bennett JE.
    J Infect Dis; 2002 Sep 15; 186(6):834-8. PubMed ID: 12198619
    [Abstract] [Full Text] [Related]

  • 16. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL, Palivizumab Long-Term Respiratory Outcomes Study Group.
    J Pediatr; 2007 Jul 15; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul 15; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

  • 20. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A, Lau H, Magar R, Wang L, Devercelli G.
    Clin Ther; 1999 Apr 15; 21(4):752-66. PubMed ID: 10363740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.